Edition:
United Kingdom

argenx NV (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

58.53USD
5:03pm GMT
Change (% chg)

$0.32 (+0.55%)
Prev Close
$58.21
Open
$57.35
Day's High
$59.00
Day's Low
$57.16
Volume
63,667
Avg. Vol
29,872
52-wk High
$69.00
52-wk Low
$17.42

Latest Key Developments (Source: Significant Developments)

Argenx Raises About $231 Mln In Gross Proceeds In Upsized U.S. Offering
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Argenx Nv ::ARGENX RAISES APPROXIMATELY $231 MILLION IN GROSS PROCEEDS IN AN UPSIZED U.S. PUBLIC OFFERING.‍ARGENX HAS GRANTED UNDERWRITERS AN OPTION TO PURCHASE UP TO AN ADDITIONAL 666,000 ADSS​.‍PRICING OF ITS PUBLIC OFFERING IN UNITED STATES WITH ANTICIPATED GROSS PROCEEDS ABOUT $231 MILLION FROM SALE OF 4,440,000 ADSS, AT $52/ADS​.  Full Article

Argenx Announces Updated Size Of Proposed Public Offering In The U.S. To 3.5 Million ADSS
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Argenx Nv ::HAS UPDATED NUMBER OF AMERICAN DEPOSITARY SHARES ("ADSS") IN ITS UNDERWRITTEN U.S. PUBLIC OFFERING (OFFERING) TO 3.5 MILLION ADSS.NOMINAL VALUE OF EUR 0.10 PER SHARE.ALL OF ADSS IN PROPOSED OFFERING ARE TO BE SOLD BY ARGENX..  Full Article

Argenx Files For Offering Of Up To $150 Mln American Depositary Shares
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Argenx Nv ::ARGENX FILES FOR OFFERING OF UPTO $150.0 MILLION OF AMERICAN DEPOSITARY SHARES - SEC FILING.  Full Article

Argenx announces launch of proposed public offering in United States
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Argenx Nv ::ARGENX ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING IN THE UNITED STATES.ARGENX NV - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF AMERICAN DEPOSITARY SHARES.ARGENX NV - EACH OF ADSS OFFERED IN OFFERING REPRESENTS RIGHT TO RECEIVE ONE ORDINARY SHARE, NOMINAL VALUE OF EUR 0.10 PER SHARE.  Full Article

Argenx To Provide Updates On Phase 1/2 Clinical Trials Of ARGX-110
Monday, 11 Dec 2017 

Dec 11 (Reuters) - ARGENX NV ::TO PROVIDE UPDATES ON PHASE 1/2 CLINICAL TRIALS OF ARGX-110 IN ACUTE MYELOID LEUKEMIA AND CUTANEOUS T-CELL LYMPHOMA DURING AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.  Full Article

Argenx Reports Positive Topline Results From Phase 2 Trial Of ARGX-113
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Argenx Nv ::REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF ARGX-113.FAVORABLE TOLERABILITY PROFILE CONSISTENT WITH PHASE 1 DATA.ARGX-113 TREATMENT RESULTED IN A STRONG CLINICAL IMPROVEMENT OVER PLACEBO DURING ENTIRE DURATION OF STUDY.75% OF ARGX-113 TREATED PATIENTS HAD SIGNIFICANT IMPROVEMENT IN 6 WEEKS VERSUS 25% OF PATIENTS ON PLACEBO.TOPLINE DATA FOR ITP TRIAL EXPECTED IN H2 2018.INTERIM DATA FROM PV TRIAL EXPECTED IN H2 2018.ARGX-113 (EFGARTIGIMOD) IS USED IN GENERALIZED MYASTHENIA GRAVIS.  Full Article

Argenx launches phase I trial with subcutaneous formulation of ARGX-113​
Monday, 30 Oct 2017 

Oct 30 (Reuters) - ARGENX NV ::‍ARGENX LAUNCHES PHASE I TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113​.‍PHASE I CLINICAL TRIAL WILL ENROLL UP TO 32 HEALTHY VOLUNTEERS​.‍TOPLINE DATA FOR MYASTHENIA GRAVIS AND IMMUNE THROMBOCYTOPENIA EXPECTED IN Q1 AND SECOND HALF OF 2018.‍INTERIM RESULTS FROM PEMPHIGUS VULGARIS TRIAL EXPECTED DURING SECOND HALF OF 2018.​.  Full Article

Argenx 9M total comprehensive loss widens to 16.5 million euros
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - ARGENX NV ::REG-ARGENX REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.9M TOTAL OPERATING INCOME EUR ‍​30.5 MILLION VERSUS EUR 12.5 MILLION YEAR AGO.9M TOTAL COMPREHENSIVE LOSS OF €16.5 MILLION (SEPTEMBER 30, 2016: LOSS €12.6 MILLION).‍​.AS OF SEPT 30 CASH POSITION OF €161.7 MILLION‍​.  Full Article

arGEN X cash position at June end doubles to 108.7 mln euros
Friday, 26 Aug 2016 

arGEN X BV : Q2 revenue is 5.7 million euros ($6.4 million) versus 2.7 million euros year ago . Q2 total operating income is 7.0 million euros versus 4.3 million euros a year ago . Q2 net loss is 7.4 million euros versus loss of 7.0 million euros a year ago . At June 30 cash position of 108.7 million euros (cash, cash-equivalents and financial assets) versus 50.5 million euros a year ago . Phase 2 study in first auto-immune indication planned to start by year-end . Cash position strengthened by $40 million upfront payment from AbbVie and 30 million euros private placement .On ARGX-110 t-cell lymphoma (TCL) - top line date to be presented by end 2016, first combination study to start in H2 2016.  Full Article

ArGEN X announces presentation of updated ARGX-110 phase 1 data in TCL at EHA 2016
Friday, 10 Jun 2016 

ArGEN X Bv :ArGEN X announces presentation of updated ARGX-110 phase 1 data in patients with T-cell lymphoma (TCL) at European Hematology Association (EHA) 2016.  Full Article

BRIEF-Argenx Raises About $231 Mln In Gross Proceeds In Upsized U.S. Offering

* ARGENX RAISES APPROXIMATELY $231 MILLION IN GROSS PROCEEDS IN AN UPSIZED U.S. PUBLIC OFFERING